Urocortin-2
Also known as: SRP, Stresscopin-related peptide, Ucn2, Urocortin II
Source Urocortin-2 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Urocortin‑2 (Ucn2) is a 38‑amino‑acid endogenous peptide that activates CRF2 receptors. It has been investigated for cardiovascular benefits, particularly in heart‑failure patients, and for metabolic effects such as improved glucose tolerance.
Mechanism of Action
Selective agonist of the CRF2 (corticotropin‑releasing factor 2) receptor, stimulating cAMP‑mediated signaling pathways
Routes of Administration
Goals & Uses
- Heart failure treatmentCardiovascularModerate
- Stress response modulationNeuropsychiatricLow
- Metabolic syndrome improvementMetabolicLow
- Muscle preservation / anabolic effectsMusculoskeletalLow
- Vasodilation and afterload reductionCardiovascularModerate
- Appetite suppression / weight regulationMetabolicLow
Contraindications
- HypovolemiaCardiovascularHigh
- Obstructive cardiomyopathyCardiovascularModerate
- Hypersensitivity to Ucn2 or CRF-family peptidesAllergy/ImmunologyHigh
- Known hypersensitivity to urocortin‑2 or formulation excipientsAllergicHigh
- Severe hypotensionCardiovascularHigh
Adverse Effects
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularCommonLow blood pressure
- FlushingVascularCommonWarmth and redness of the skin
- TachycardiaCardiovascularUncommonAbnormally fast heart rate
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- Antihypertensive agentsModerate
- CRF1R antagonistsLow
- Beta‑blockersModerate
- Vasodilators (e.g., nitrates, hydralazine)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorization only; not marketed.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalNo marketing authorization; used under clinical trial regulations.
Not approved for clinical use in any jurisdiction; studied in early‑phase clinical trials for chronic heart failure and metabolic disorders.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Urocortin-2?
Urocortin‑2 (Ucn2) is a 38‑amino‑acid endogenous peptide that activates CRF2 receptors. It has been investigated for cardiovascular benefits, particularly in heart‑failure patients, and for metabolic effects such as improved glucose tolerance.
What is Urocortin-2 used for?
Urocortin-2 is educationally associated with: Heart failure treatment, Stress response modulation, Metabolic syndrome improvement, Muscle preservation / anabolic effects, Vasodilation and afterload reduction, Appetite suppression / weight regulation. Educational only — not medical advice.
How is Urocortin-2 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Urocortin-2?
Reported adverse effects include: Headache, Hypotension, Flushing, Tachycardia, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Urocortin-2?
Recorded contraindications: Hypovolemia, Obstructive cardiomyopathy, Hypersensitivity to Ucn2 or CRF-family peptides, Known hypersensitivity to urocortin‑2 or formulation excipients, Severe hypotension. Consult a qualified clinician before use.